Hemlibra 105 mg/0.7 ml (SC Injection)
105 mg vial: ৳ 241,682.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Emicizumab |
| Company | Roche bangladesh ltd |
| Also available as |
Indications
- Routine prophylaxis for hemophilia A patients
Pharmacology
- Mimics coagulation factor VIII
- Binds to activated Factor IX and Factor X
- Activates coagulation cascade
- Reduces hemorrhagic episodes
Dosage & Administration
- Loading dose: 3 mg/kg once weekly for first 4 weeks
- Maintenance dose options: 1.5 mg/kg once weekly, or 3 mg/kg once every two weeks, or 6 mg/kg once every four weeks
Interaction
- Hypercoagulability with concomitant use of aPCC
Side Effects
- Thrombotic microangiopathy
- Thromboembolism
- Immunogenicity
Pregnancy & Lactation
- Unknown risk in pregnant women
- Emicizumab presence in human milk is unknown
- Consider benefits of breastfeeding vs. use of emicizumab
Precautions & Warnings
- Immunogenicity of anti-Hemlibra antibodies
- Interference with laboratory coagulation tests
Storage Conditions
- Store in refrigerator at 2°C to 8°C
- Do not freeze
- Do not shake
- Discard if not used immediately after removal from vial